found that inhibition of the AKT pathway does not sensitize B-cell lymphoma venetoclax-resistant cells with the upregulation of BCL-XL mediated by the AKT pathway, which suggests that treatments targeting the AKT pathway in combination with a BCL-XL inhibitor may be a better therapeutic option. This evidence concerns the gene BCL2L1 and B-cell non-Hodgkin lymphoma.